And of those 39 US-based biotech companies, five of them are from San Diego, highlighting the region’s growing importance as hub for the biotech and life science industries.
According to a recently authored BIO article in the Union Tribune San Diego, there are several reasons at play for the strong public offerings – enactment of the JOBS Act, an eager investor market and increasing regulatory transparency resulting from PDUFA V.
As powerful as the JOBS Act has been at spurring investment and job creation in the biotech sector, other legislative proposals have the potential to have a similarly positive impact. One such proposal is the Start-up Jobs and Innovation Act, which would allow investors to claim the losses that pre-revenue companies generate while bringing a new product to market.
Last month, the Coalition of Small Business Innovators (of which BIO is a member), held at forum at the National Press Club to discuss how this act will be beneficial for all small business innovators, including those in biotech. I encourage you to watch the full video here.
If you enjoy hearing about public policies, regulatory, and capital market issues affecting the biotech industry, you’re in luck. The JOBS Act and other timely policy issues will be discussed at the upcoming 2014 BIO International Convention. To learn more about the evolving program, please visit here.
In addition to targeted educational sessions and Specialty Forums, the event will feature Keynotes, premier networking opportunities, the chance to connect with thousands of companies through BIO One-on-One PartneringTM meetings as well as the world’s largest biotechnology exhibition – the BIO Exhibition.
Registration is now open.